Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Allogene Therapeutics, Inc.

ALLO Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2018โ€“FY2025

Last close ยท Oct 23, 2026

$1.25

0.0%
Compare
Revenue Total sales reported in the income statement.
$0.0M
100.0% vs prior year
Operating margin Operating income as a share of revenue.
โ€”
Net income Profit after all expenses, interest and tax.
โˆ’$191M
Free cash flow Cash from operations minus capital spending.
โˆ’$150M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$411M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$0.67 EPS (TTM)

What Allogene Therapeutics, Inc. does

No business description yet.

Legal name
Allogene Therapeutics, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Mar 12, 2026
Accession ยท CIK
0001628280-26-017242
0001737287

Revenue and margins

Allogene Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$150M in fiscal 2025, โ€” of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Allogene Therapeutics, Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 13.2%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Allogene Therapeutics, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $457M$517M$449M$292M$250M
Interest coverage โ€”โ€”โ€”โˆ’1,509.4xโˆ’194.7x
Current ratio 9.8x9.8x12.4x8.5x7.9x
Quick ratio 9.8x9.8x12.4x8.5x7.9x
Total assets $1.1B$822M$643M$549M$416M
Total liabilities $126M$155M$131M$127M$123M
Shareholders' equity $925M$667M$512M$422M$293M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ“ โœ• โœ“ โœ• โœ• โœ“ โœ“
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ• โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โœ“ โœ• โœ“ โœ“ โœ“ โœ• โœ•
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โ€” โœ• โœ“ โœ• โœ• โœ• โœ•
F-score โ€” / 3โ€” / 61 / 73 / 72 / 72 / 72 / 72 / 7
Accruals ratio โˆ’21.6%โˆ’6.3%โˆ’20.7%0.2%โˆ’12.8%โˆ’12.2%โˆ’9.6%โˆ’8.6%
Altman Z'' 11.608.427.896.450.68โˆ’2.92โˆ’7.45โˆ’13.10

8 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue โ€” $0.0M $0.0M $114M $0.2M $0.1M $0.0M $0.0M
Research and development $152M $145M $193M $220M $256M $243M $192M $150M
Operating income โˆ’$193M โˆ’$202M โˆ’$258M โˆ’$180M โˆ’$336M โˆ’$328M โˆ’$273M โˆ’$209M
Interest expense $3.4M $0.0M $0.0M โ€” โ€” $0.0M $0.2M $1.1M
Pretax income โˆ’$212M โˆ’$185M โˆ’$250M โˆ’$257M โ€” โˆ’$327M โˆ’$257M โˆ’$191M
Income tax โˆ’$0.1M โˆ’$0.3M $0.0M $0.0M $0.0M $0.0M $0.4M $0.0M
Net income โˆ’$212M โˆ’$185M โˆ’$316M โˆ’$182M โˆ’$340M โˆ’$327M โˆ’$258M โˆ’$191M
Diluted EPS โˆ’$7.31 โˆ’$1.83 โˆ’$2.63 โˆ’$1.34 โˆ’$2.38 โˆ’$2.09 โˆ’$1.32 โˆ’$0.87
Diluted shares 0.03B 0.10B 0.12B 0.14B 0.14B 0.16B 0.19B 0.22B
Cash flow
Cash from operations โˆ’$44.7M โˆ’$137M โˆ’$115M โˆ’$185M โˆ’$221M โˆ’$238M โˆ’$200M โˆ’$149M
Capital expenditure $3.2M $50.8M $66.0M $21.4M $5.2M $1.5M $0.7M $0.4M
Free cash flow โˆ’$47.9M โˆ’$188M โˆ’$181M โˆ’$206M โˆ’$226M โˆ’$239M โˆ’$201M โˆ’$150M
Depreciation and amortization $1.0M $4.6M $7.4M $10.5M $14.3M $14.2M $13.6M $12.4M
Stock-based compensation $18.6M $46.1M $65.3M $80.8M $83.6M $66.0M $51.7M $37.6M
Balance sheet
Cash and short-term investments $459M $531M $828M $457M $517M $449M $292M $250M
Current assets $468M $545M $845M $471M $529M $459M $303M $258M
Current liabilities $29.5M $33.1M $94.3M $47.9M $53.7M $37.1M $35.5M $32.5M
Property and equipment, net $8.6M $56.4M $119M $123M $113M $99.5M $86.1M $72.8M
Intangible assets $0.8M $0.2M $0.0M โ€” โ€” โ€” โ€” โ€”
Total assets $774M $718M $1.2B $1.1B $822M $643M $549M $416M
Total liabilities $70.7M $88.8M $148M $126M $155M $131M $127M $123M
Preferred stock $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $703M $629M $1.0B $925M $667M $512M $422M $293M
Margins
Operating margin โ€” โ€” โ€” โˆ’157.9% โˆ’215,087.2% โˆ’344,986.3% โˆ’1,241,813.6% โ€”
EBITDA margin โ€” โ€” โ€” โˆ’148.7% โˆ’205,920.5% โˆ’330,040.0% โˆ’1,179,818.2% โ€”
Net margin โ€” โ€” โ€” โˆ’159.6% โˆ’218,214.1% โˆ’344,489.5% โˆ’1,170,863.6% โ€”
FCF margin โ€” โ€” โ€” โˆ’180.8% โˆ’144,685.9% โˆ’251,841.1% โˆ’913,609.1% โ€”
Returns
Return on capital employed โˆ’25.9% โˆ’29.5% โˆ’22.8% โˆ’18.0% โˆ’43.7% โˆ’54.1% โˆ’53.2% โˆ’54.6%
Return on equity โˆ’30.1% โˆ’27.7% โˆ’38.5% โˆ’18.8% โˆ’42.8% โˆ’55.5% โˆ’55.1% โˆ’53.4%
Return on assets โˆ’27.3% โˆ’24.8% โˆ’32.5% โˆ’16.0% โˆ’36.4% โˆ’44.7% โˆ’43.2% โˆ’39.6%
Return on tangible equity โˆ’30.1% โˆ’29.4% โˆ’31.2% โˆ’19.7% โˆ’51.0% โˆ’63.9% โˆ’61.0% โˆ’65.3%
Growth
Revenue growth โ€” โ€” โ€” โ€” โˆ’99.9% โˆ’39.1% โˆ’76.8% โˆ’100.0%
Share count change โ€” 249.1% 19.1% 12.8% 5.4% 9.6% 24.1% 13.2%
Financial health
Interest coverage โˆ’57.4x โ€” โ€” โ€” โ€” โ€” โˆ’1,509.4x โˆ’194.7x
Current ratio 15.9x 16.5x 9.0x 9.8x 9.8x 12.4x 8.5x 7.9x
Quick ratio 15.9x 16.5x 9.0x 9.8x 9.8x 12.4x 8.5x 7.9x
Capital allocation
Capex / revenue โ€” โ€” โ€” 18.8% 3,327.6% 1,595.8% 3,154.5% โ€”
Stock comp / revenue โ€” โ€” โ€” 70.8% 53,589.7% 69,422.1% 235,195.5% โ€”
Quality scores
Piotroski F-score โ€” โ€” 1.0 3.0 2.0 2.0 2.0 2.0
Altman Z'' 11.6 8.4 7.9 6.4 0.7 โˆ’2.9 โˆ’7.5 โˆ’13.1
Accruals ratio โˆ’21.6% โˆ’6.3% โˆ’20.7% 0.2% โˆ’12.8% โˆ’12.2% โˆ’9.6% โˆ’8.6%

Source: SEC EDGAR XBRL filings (CIK 0001737287). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open